tetano
Editor, Senior Moderator
Br J Cancer
. 2021 Aug 16.
doi: 10.1038/s41416-021-01500-z. Online ahead of print.
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
Beth Russell[SUP] #[/SUP][SUP] 1 [/SUP], Charlotte L Moss[SUP] #[/SUP][SUP] 2 [/SUP], Vallari Shah[SUP] 3 [/SUP], Thinzar Ko Ko[SUP] 3 [/SUP], Kieran Palmer[SUP] 4 [/SUP], Rushan Sylva[SUP] 5 [/SUP], Gincy George[SUP] 2 [/SUP], Maria J Monroy-Iglesias[SUP] 2 [/SUP], Piers Patten[SUP] 3 6 [/SUP], Muhammed Mansour Ceesay[SUP] 7 [/SUP], Reuben Benjamin[SUP] 3 6 [/SUP], Victoria Potter[SUP] 3 [/SUP], Antonio Pagliuca[SUP] 3 6 [/SUP], Sophie Papa[SUP] 5 6 [/SUP], Sheeba Irshad[SUP] 5 6 [/SUP], Paul Ross[SUP] 5 [/SUP], James Spicer[SUP] 5 6 [/SUP], Shahram Kordasti[SUP] 6 8 [/SUP], Danielle Crawley[SUP] 2 5 [/SUP], Harriet Wylie[SUP] 2 [/SUP], Fidelma Cahill[SUP] 2 [/SUP], Anna Haire[SUP] 2 [/SUP], Kamarul Zaki[SUP] 5 [/SUP], Ailsa Sita-Lumsden[SUP] 5 [/SUP], Debra Josephs[SUP] 2 5 [/SUP], Deborah Enting[SUP] 2 5 [/SUP], Angela Swampillai[SUP] 5 [/SUP], Elinor Sawyer[SUP] 6 9 [/SUP], Andrea D'Souza[SUP] 5 [/SUP], Simon Gomberg[SUP] 5 [/SUP], Claire Harrison[SUP] 8 [/SUP], Paul Fields[SUP] 8 [/SUP], David Wrench[SUP] 8 [/SUP], Anne Rigg[SUP] 5 [/SUP], Richard Sullivan[SUP] 6 [/SUP], Austin Kulasekararaj[SUP] 3 6 [/SUP], Guy’s Cancer Real World Evidence; Saoirse Dolly[SUP] 5 [/SUP], Mieke Van Hemelrijck[SUP] 2 5 [/SUP]
Collaborators, Affiliations
Abstract
Background: Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death.
Methods: Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality.
Results: Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR): 1.97 (95% confidence interval (CI): 1.15-3.38)], Asian ethnicity [3.42 (1. 59-7.35)], haematological cancer [2.03 (1.16-3.56)] and a cancer diagnosis for >2-5 years [2.81 (1.41-5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis).
Conclusions: Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients.
. 2021 Aug 16.
doi: 10.1038/s41416-021-01500-z. Online ahead of print.
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
Beth Russell[SUP] #[/SUP][SUP] 1 [/SUP], Charlotte L Moss[SUP] #[/SUP][SUP] 2 [/SUP], Vallari Shah[SUP] 3 [/SUP], Thinzar Ko Ko[SUP] 3 [/SUP], Kieran Palmer[SUP] 4 [/SUP], Rushan Sylva[SUP] 5 [/SUP], Gincy George[SUP] 2 [/SUP], Maria J Monroy-Iglesias[SUP] 2 [/SUP], Piers Patten[SUP] 3 6 [/SUP], Muhammed Mansour Ceesay[SUP] 7 [/SUP], Reuben Benjamin[SUP] 3 6 [/SUP], Victoria Potter[SUP] 3 [/SUP], Antonio Pagliuca[SUP] 3 6 [/SUP], Sophie Papa[SUP] 5 6 [/SUP], Sheeba Irshad[SUP] 5 6 [/SUP], Paul Ross[SUP] 5 [/SUP], James Spicer[SUP] 5 6 [/SUP], Shahram Kordasti[SUP] 6 8 [/SUP], Danielle Crawley[SUP] 2 5 [/SUP], Harriet Wylie[SUP] 2 [/SUP], Fidelma Cahill[SUP] 2 [/SUP], Anna Haire[SUP] 2 [/SUP], Kamarul Zaki[SUP] 5 [/SUP], Ailsa Sita-Lumsden[SUP] 5 [/SUP], Debra Josephs[SUP] 2 5 [/SUP], Deborah Enting[SUP] 2 5 [/SUP], Angela Swampillai[SUP] 5 [/SUP], Elinor Sawyer[SUP] 6 9 [/SUP], Andrea D'Souza[SUP] 5 [/SUP], Simon Gomberg[SUP] 5 [/SUP], Claire Harrison[SUP] 8 [/SUP], Paul Fields[SUP] 8 [/SUP], David Wrench[SUP] 8 [/SUP], Anne Rigg[SUP] 5 [/SUP], Richard Sullivan[SUP] 6 [/SUP], Austin Kulasekararaj[SUP] 3 6 [/SUP], Guy’s Cancer Real World Evidence; Saoirse Dolly[SUP] 5 [/SUP], Mieke Van Hemelrijck[SUP] 2 5 [/SUP]
Collaborators, Affiliations
- PMID: 34400804
- DOI: 10.1038/s41416-021-01500-z
Abstract
Background: Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death.
Methods: Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality.
Results: Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR): 1.97 (95% confidence interval (CI): 1.15-3.38)], Asian ethnicity [3.42 (1. 59-7.35)], haematological cancer [2.03 (1.16-3.56)] and a cancer diagnosis for >2-5 years [2.81 (1.41-5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis).
Conclusions: Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients.